Literature DB >> 16276421

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Tae-Wook Chun1, David C Nickle, J Shawn Justement, Danielle Large, Alice Semerjian, Marcel E Curlin, M Angeline O'Shea, Claire W Hallahan, Marybeth Daucher, Douglas J Ward, Susan Moir, James I Mullins, Colin Kovacs, Anthony S Fauci.   

Abstract

The persistence of latently infected, resting CD4+ T cells is considered to be a major obstacle in preventing the eradication of HIV-1 even in patients who have received effective antiviral therapy for an average duration of 5 years. Although previous studies have suggested that the latent HIV reservoir in the resting CD4+ T cell compartment is virologically quiescent in the absence of activating stimuli, evidence has been mounting to suggest that low levels of ongoing viral replication persist and in turn, prolong the overall half-life of HIV in patients receiving antiviral therapy. Here, we demonstrate the persistence of replication-competent virus in CD4+ T cells in a cohort of patients who had received uninterrupted antiviral therapy for up to 9.1 years that rendered them consistently aviremic throughout that time. Surprisingly, substantially higher levels of HIV proviral DNA were found in activated CD4+ T cells when compared with resting CD4+ T cells in the majority of patients we studied. Phylogenetic analyses revealed evidence for cross infection between the resting and activated CD4+ T cell compartments, suggesting that ongoing reactivation of latently infected, resting CD4+ T cells and spread of virus by activated CD4+ T cells may occur in these patients. Such events may allow continual replenishment of the CD4+ T cell reservoir and resetting of the half-life of the latently infected, resting CD4+ T cells despite prolonged periods of aviremia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16276421      PMCID: PMC1265878          DOI: 10.1172/JCI26197

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy.

Authors:  V Natarajan; M Bosche; J A Metcalf; D J Ward; H C Lane; J A Kovacs
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

2.  IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Authors:  Feng-Xiang Wang; Yan Xu; Julie Sullivan; Emily Souder; Elias G Argyris; Edward A Acheampong; Jaime Fisher; Maria Sierra; Michael M Thomson; Rafael Najera; Ian Frank; Joseph Kulkosky; Roger J Pomerantz; Giuseppe Nunnari
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

3.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

Authors:  Mark Sharkey; Karine Triques; Daniel R Kuritzkes; Mario Stevenson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

6.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

7.  Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.

Authors:  T W Chun; D Engel; S B Mizell; C W Hallahan; M Fischette; S Park; R T Davey; M Dybul; J A Kovacs; J A Metcalf; J M Mican; M M Berrey; L Corey; H C Lane; A S Fauci
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

8.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

9.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Authors:  M E Sharkey; I Teo; T Greenough; N Sharova; K Luzuriaga; J L Sullivan; R P Bucy; L G Kostrikis; A Haase; C Veryard; R E Davaro; S H Cheeseman; J S Daly; C Bova; R T Ellison; B Mady; K K Lai; G Moyle; M Nelson; B Gazzard; S Shaunak; M Stevenson
Journal:  Nat Med       Date:  2000-01       Impact factor: 87.241

10.  Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines.

Authors:  T W Chun; D Engel; S B Mizell; L A Ehler; A S Fauci
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

View more
  152 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

Review 2.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Authors:  Daniel Mendoza; Sarah A Johnson; Bennett A Peterson; Ven Natarajan; Maria Salgado; Robin L Dewar; Peter D Burbelo; Nicole A Doria-Rose; Erin H Graf; Jamieson H Greenwald; Jessica N Hodge; William L Thompson; Nancy A Cogliano; Cheryl L Chairez; Catherine A Rehm; Sara Jones; Claire W Hallahan; Joseph A Kovacs; Irini Sereti; Omar Sued; Sheila A Peel; Robert J O'Connell; Una O'Doherty; Tae-Wook Chun; Mark Connors; Stephen A Migueles
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

4.  HIV-1 proviral DNA loads (as determined by quantitative PCR) in patients subjected to structured treatment interruption after antiretroviral therapy failure.

Authors:  Shirley V Komninakis; Domingos E M Santos; Carlos Santos; Márcia P R Oliveros; Sabri Sanabani; Ricardo S Diaz
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

5.  Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.

Authors:  Jana Blazkova; Tae-Wook Chun; Bietel W Belay; Danielle Murray; J Shawn Justement; Emily K Funk; Amy Nelson; Claire W Hallahan; Susan Moir; Paul A Wender; Anthony S Fauci
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

6.  Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.

Authors:  Paul U Cameron; Suha Saleh; Georgina Sallmann; Ajantha Solomon; Fiona Wightman; Vanessa A Evans; Genevieve Boucher; Elias K Haddad; Rafick-Pierre Sekaly; Andrew N Harman; Jenny L Anderson; Kate L Jones; Johnson Mak; Anthony L Cunningham; Anthony Jaworowski; Sharon R Lewin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

7.  HIV load testing with small samples of whole blood.

Authors:  Katrin Steinmetzer; Thomas Seidel; Andreas Stallmach; Eugen Ermantraut
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

Review 8.  Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.

Authors:  Corrilynn O Hileman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

9.  Interleukin-7 promotes HIV persistence during antiretroviral therapy.

Authors:  Claire Vandergeeten; Rémi Fromentin; Sandrina DaFonseca; Mariam B Lawani; Irini Sereti; Michael M Lederman; Moti Ramgopal; Jean-Pierre Routy; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

Review 10.  Cellular reservoirs of HIV-1 and their role in viral persistence.

Authors:  Aikaterini Alexaki; Yujie Liu; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.